Gantenerumab fails; time for Roche to cut its Alzheimer's losses?
This article was originally published in Scrip
Executive Summary
Roche is dropping a Phase III trial of the anti-amyloid gantenerumab in prodromal Alzheimer's disease patients. The decision calls into question not only the future of this drug, but also that of other disease modifying anti-amyloids, including Roche's crenezumab.
You may also be interested in...
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Scottish Funding No For Two Orphans As SMC Tries To Catch Up After COVID-19 Backlog
Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.
Cuban COVID-19 Vaccines To Come Under WHO Scrutiny
The Cuban government has approved the country’s home grown COVID-19 vaccine for emergency use in children, while Mexico is poised to authorize another Cuban vaccine.